SCHEMBL475666

SCHEMBL475666

CN(c1cc(C(=O)O)cc(C(=O)NCCc2ccccc2)c1)S(C)(=O)=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 1/20 0.58
RAB9A P51151 10/20 0.55
NPC1 O15118 8/20 0.55
ALDH1A1 P00352 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
TP53 P04637 1/20 0.55
HDAC2 Q92769 2/20 0.51
HDAC8 Q9BY41 2/20 0.51
HDAC6 Q9UBN7 2/20 0.51
HDAC3 O15379 1/20 0.51
HDAC4 P56524 1/20 0.51
HDAC1 Q13547 1/20 0.51
HDAC7 Q8WUI4 1/20 0.51
HDAC10 Q969S8 1/20 0.51
HDAC11 Q96DB2 1/20 0.51
HDAC9 Q9UKV0 1/20 0.51
HDAC5 Q9UQL6 1/20 0.51
BACE1 P56817 3/20 0.49
KDM4E B2RXH2 3/20 0.49
KDM5A P29375 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3645315 0.91 MCHR1 (0.56) MCHR1RAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL4694649 0.90 MCHR1 (0.55) MCHR1RAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL3344982 0.82 RAB9A (0.76) MCHR1RAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL4750119 0.81 SMN1; SMN2 (0.50) RAB9ANPC1ALDH1A1SMN1; SMN2TP53
SCHEMBL3351696 0.80 HDAC2 (0.52) RAB9ANPC1ALDH1A1SMN1; SMN2TP53
SCHEMBL3345017 0.79 RAB9A (0.72) RAB9ANPC1SMN1; SMN2HDAC2HDAC8
SCHEMBL3645938 0.79 BACE1 (0.65) BACE1
SCHEMBL3349870 0.79 HDAC2 (0.51) MCHR1RAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL3646488 0.78 LMNA (0.55) RAB9ANPC1ALDH1A1SMN1; SMN2MEN1
SCHEMBL3643931 0.78 CA1 (0.59) RAB9ANPC1BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014036105-A2 INHIBITORS OF MEMAPSIN 2 CLEAVAGE FOR THE TREATMENT OF ALZHEIMER'S DISEASE OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) 2014-03-06 WO disclosed
EP-2486006-A1 SULFONAMIDO PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2012-08-15 EP disclosed
EP-2411000-A1 PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2012-02-01 EP disclosed
EP-2349244-A1 PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2011-08-03 EP disclosed
WO-2011044057-A1 SULFONAMIDO PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2011-04-14 WO disclosed
WO-2010110817-A1 PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2010-09-30 WO disclosed
EP-2178837-A2 ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY COMENTIS, INC. (US) 2010-04-28 EP disclosed
WO-2010042030-A1 ASPARTYL PROTEASE INHIBITORS MEDIVIR AB (SE) 2010-04-15 WO disclosed
WO-2010042892-A1 PYRROLIDINE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2010-04-15 WO disclosed
WO-2009015369-A2 COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2009-01-29 WO disclosed
EP-1871739-A1 COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2008-01-02 EP disclosed
WO-2006110668-A1 COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2006-10-19 WO disclosed